Replies to post #400760 on Innovation Pharmaceuticals Inc (IPIX)

[realscottsmith]

Expecting a 50 percent plus haircut tomorrow.

Item 1.02 Termination of a Material Definitive Agreement.

On December 1, 2023, Alfasigma S.p.A. (“Alfasigma”) notified Innovation Pharmaceuticals Inc. (the “Company”) of its termination without cause of the Exclusive License Agreement between the parties dated July 18, 2019 (the “License Agreement”), which granted Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS). A description of the License Agreement is set forth in the Current Report on Form 8-K filed by the Company on July 22, 2019 and is incorporated herein by reference. Alfasigma terminated the License Agreement following its decision to discontinue further work under the License Agreement. On December 4, 2023, the parties entered into a mutual release relating to the License Agreement and the Company waived the 60-day notice period for terminations without cause by Alfasigma.

[loanranger]

Are you braggin' or complainin'?

IPIX is now free to pursue this:
https://static1.squarespace.com/static/5715352e20c647639137f992/t/5beac1250ebbe846eb4b031e/1542111528589/IPI+IBD+Innovate+2018+Poster+%28final%29.pdf

All the CEO CPA has to do is scrape together some funds and duplicate those results, no? Maybe he can terminate the unfiled BeaMed Agreement by returning some preferred shares and get some cash back.

Of course if it was that easy I guess AlfaSigma wouldn't have bailed.

Hold on. Would you like to suggest that AS was afraid that IPIX would hurt their procspects by breaking out its vaunted oral B fo IBD?

[frenchbroad]

I am not unhappy to be divorce from Alfasigma. They start only 1 EU clinical trial in 2022 and 0 in 2023. They buy 2 different company and 1 other drug since 2022. They maybe do not have much money for a new clinical trial for a Brilacidin Ulcerative Proctitis malady with limited market. They also had first refusal privilege for other Brilacidin potentials. Ipix now is free to find an other better partner for the things Brilacidin can help in gastroenterology.